ATIVAN TABLET

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

LORAZEPAM

थमां उपलब्ध:

PFIZER CANADA ULC

ए.टी.सी कोड:

N05BA06

INN (इंटरनेशनल नाम):

LORAZEPAM

डोज़:

0.5MG

फार्मास्यूटिकल फॉर्म:

TABLET

रचना:

LORAZEPAM 0.5MG

प्रशासन का मार्ग:

ORAL

पैकेज में यूनिट:

100/500

प्रिस्क्रिप्शन प्रकार:

Targeted (CDSA IV)

चिकित्सीय क्षेत्र:

BENZODIAZEPINES

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0110731003; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2003-04-02

उत्पाद विशेषताएं

                                _Product Monograph _
_ _
_ATIVAN (lorazepam) _
_Page 1 of 32 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
ATIVAN
®
Lorazepam
Tablets, 0.5 mg, 1 mg, 2 mg, Oral
Tablets, 0.5 mg, 1 mg, 2 mg, Sublingual
Anxiolytic-Sedative
Pfizer Canada ULC
17,300 Trans Canada Highway
Kirkland, QC H9J 2M5
Date of Initial Authorization:
FEB 4, 1977
Date of Revision:
DEC 28, 2022
Submission Control Number: 267182
®
T.M. Wyeth
Pfizer Canada ULC, Licensee
©
Pfizer Canada ULC
_ _
_Product Monograph _
_ _
_ATIVAN (lorazepam) _
_Page 2 of 32 _
RECENT MAJOR LABEL CHANGES
1 INDICATIONS, 1.2 Geriatrics
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dosage and
Dosage Adjustment
7 WARNINGS AND PRECAUTIONS, Dependence/Tolerance
7 WARNINGS AND PRECAUTIONS, Withdrawal
7 WARNINGS AND PRECAUTIONS, Immune
7 WARNINGS AND PRECAUTIONS, Neurologic, Falls and Fractures
7 WARNINGS AND PRECAUTIONS, Risks from Concomitant use of
Opioids and Benzodiazepines
7 WARNINGS AND PRECAUTIONS, 7.1. Special Populations, 7.1.3
Pediatrics
7 WARNINGS AND PRECAUTIONS, 7.1. Special Populations, 7.1.4
Geriatrics
12/2022
3 SERIOUS WARNINGS AND PRECAUTIONS BOX, Addiction, Abuse
and Misuse
4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dosage and
Dosage Adjustment
7 WARNINGS AND PRECAUTIONS, Withdrawal
12/2022
_ _
_Product Monograph _
_ _
_ATIVAN (lorazepam) _
_Page 3 of 32 _
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
3
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
5
1
INDICATIONS
..............................................................
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 28-12-2022

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें